Navigation Links
Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
Date:7/28/2009

ion enhancements will be successful or will effectively simplify or expand the use of product candidates or technologies, that the GAM technology can be successfully broadened or applied to additional wound healing or tissue repair opportunities, that Excellarate or our other candidates will prove to be sufficiently safe and effective, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that clinical studies even if successful will lead to product advancement or partnering, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value, that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population, or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to releas
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardium Regains Listing Compliance with NYSE Amex
2. Cardiums InnerCool Therapies Business to Be Acquired By Royal Philips Electronics
3. Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
4. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
5. Cardium Completes $3.5 Million Credit Facility
6. Cardium Announces Retirement of Director
7. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
8. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
11. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  An entire month is dedicated ... neuropathies – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular ... extreme muscle atrophy, weakness, and foot and hand deformities. ... millions worldwide. CMT is a progressive disease, and over ... requiring mobility devices such as leg braces, wheelchairs and ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
(Date:9/19/2014)... September 19, 2014 Cereal grain ... industries will gather October 5–8, 2014, for the ... Island Convention Center in Providence, Rhode Island. The ... work of food scientists, chemists, microbiologists, nutritionists, and ... food production management. To date, 1,000 attendees have ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... March 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, ... will be held at the Ritz Carlton Laguna Niguel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
... Corp. (Nasdaq: BSTC ), a biopharmaceutical company ... it will host a conference call and live audio ... to report its fourth quarter and full year 2010 ... in the conference call, please dial 800-860-2442 (domestic) or ...
... 2011 Pioneer Surgical Technology today announces the market ... to be used in extremities and pelvis. ... 2011 American College of Foot and Ankle Surgeons (ACFAS) ... newest Biologics product, Legato™, will be included. Legato is ...
Cached Biology Technology:Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities and Pelvis Market 2
(Date:9/21/2014)... Biochemists working at the University of California, San Diego, ... chemical marks that control the activity of genes based ... report results from its application to human embryonic cells ... online September 21. , "All of our cells have ... separate functions," said John Whitaker, lead author of the ...
(Date:9/19/2014)... dinosaurs a newly discovered hadrosaur with a ... Rhinorex condrupus by paleontologists from North ... in what is now Utah approximately 75 million ... Rhinorex, which translates roughly into "King Nose," was ... Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are ...
(Date:9/19/2014)... years has adapted to the arctic cold, and then you ... for you. , This is happening to the small white ... called nonylphenol, comes from the use of certain detergents, pesticides ... disruptor, but when entering the worm it has another dangerous ... in its body from cold damage. , Enchytraeus albidus ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... obesity in the United States is reaching epidemic proportions. With ... time television devoted to foods and beverages and continuing questions ... the November/December issue of the Journal of Nutrition Education ... might be a large contributor to the problem. Researchers ...
... laboratory that deciphered the DNA codes, or genomes, of the ... Genome 10K Project, an international effort to build an invaluable ... conducting comparative studies on a scale that currently can not ... in a paper published in the Nov. 5, 2009 issue ...
... VALLEY, Calif., Oct. 19 Spectros, developer and manufacturer ... light on life-threatening diseases, announced today that it has ... Tissue Oximeter and Sensors. The markets covered include ... Suriname, Italy, France, Spain, Portugal, Poland, Greece, Turkey, and ...
Cached Biology News:TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2
... AS-2057 are fully automatic sample injection systems ... of precision. Sampling flexibility is unparalleled with ... automation and combinatorial chemistry. Also available is ... standard rack for 50 2,ml vials. The ...
... Rotofor purification system, 100-120 V, is used ... isoelectric focusing (IEF). The system includes both ... ml) focusing chambers, chassis, harvesting apparatus, cooling ... (pH 3-10), 60 ml syringe, colored protein ...
...
... SIGNETs BCIP/NBT Chromogen system consists ... chromogen in a single component,solution. ... in the presence of alkaline ... with minimal background noise. ,The ...
Biology Products: